Corrado Tarella

Dr. Corrado Tarella


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2024 in Blood Cancer Discovery
Verified
Journal Article
Closed access
CRCecilia Restelli
Cecilia Restelli
MRMarco Ruella
Marco Ruella
LPLuca Paruzzo
Luca Paruzzo
CTCorrado Tarella
Corrado Tarella
Pier Giuseppe PelicciPier Giuseppe Pelicci
Pier Giuseppe Pelicci
ECEmanuela Colombo
Emanuela Colombo
Despite advancements, acute myeloid leukemia (AML) remains unconquered by current therapies. Evidence of immune evasion during AML progression, such as HLA loss and T-cell exhaustion, suggests that antileukemic immune responses contribute to disease control and could be harnessed by immunotherapy. In this review, we discuss a spectrum of AML immunotherapy targets, encompassing cancer cell-intrinsic and surface antigens as well as targeting in the leukemic milieu, and how they can be tailored for personalized approaches. These targets are overviewed across major immunotherapy modalities applied to AML: immune checkpoint inhibitors, antibody–drug conjugates, therapeutic vaccines, bispecific/trispecific antibodies, and chimeric antigen receptor (CAR)-T and CAR-NK cells. Significance: Immune therapies in AML treatment show evolving promise. Ongoing research aims to customize approaches for varied patient profiles and clinical scenarios. This review covers immune surveillance mechanisms, therapy options like checkpoint inhibitors, antibodies, CAR-T/NK cells, and vaccines, as well as resistance mechanisms and microenvironment considerations.

24 July 2021 in Leukemia
Verified
Journal Article
Open access
PDF file
ARAlessandra Rossi
Alessandra Rossi
SOStefania Orecchioni
Stefania Orecchioni
PFPaolo Falvo
Paolo Falvo
VTValentina Tabanelli
Valentina Tabanelli
EBElena Baiardi
Elena Baiardi
EDEnrico Derenzini
Enrico Derenzini
Standard chemotherapies for diffuse large B-cell lymphoma (DLBCL), based on the induction of exogenous DNA damage and oxidative stress, are often less effective in the presence of increased MYC and BCL-2 levels, especially in the case of double hit (DH) lymphomas harboring rearrangements of the MYC and BCL-2 oncogenes, which enrich for a patient’s population characterized by refractoriness to anthracycline-based chemotherapy. Here we hypothesized that adaptive mechanisms to MYC-induced replicative and oxidative stress, consisting in DNA damage response (DDR) activation and BCL-2 overexpression, could represent the biologic basis of the poor prognosis and chemoresistance observed in MYC/BCL-2-positive lymphoma. We first integrated targeted gene expression profiling (T-GEP), fluorescence in situ hybridization (FISH) analysis, and characterization of replicative and oxidative stress biomarkers in two independent DLBCL cohorts. The presence of oxidative DNA damage biomarkers identified a poor prognosis double expresser (DE)-DLBCL subset, characterized by relatively higher BCL-2 gene expression levels and enrichment for DH lymphomas. Based on these findings, we tested therapeutic strategies based on combined DDR and BCL-2 inhibition, confirming efficacy and synergistic interactions in in vitro and in vivo DH-DLBCL models. These data provide the rationale for precision-therapy strategies based on combined DDR and BCL-2 inhibition in DH or DE-DLBCL.

11 April 2019 in Haematologica
Verified
Journal Article
Open access
PDF file
RBRiccardo Bruna
Riccardo Bruna
FBFabio Benedetti
Fabio Benedetti
CBCarola Boccomini
Carola Boccomini
CPCaterina Patti
Caterina Patti
ABAnna Maria Barbui
Anna Maria Barbui
CTCorrado Tarella
Corrado Tarella
A prospective trial conducted in 2000-2005 showed no survival advantage for high-dose chemotherapy with rituximab and autograft (R-HDS) versus conventional chemotherapy with rituximab (CHOP-R) as first-line therapy in 134 high-risk follicular lymphoma patients aged <60 year. The study has been updated at the 13-yr median follow-up. As of February 2017, 88 (66%) patients were alive, with overall survival of 66.4% at 13 years, without a significant difference between R-HDS (64.5%) and CHOP-R (68.5%). To date, 46 patients have died, mainly because of disease progression (47.8% of all deaths), secondary malignancies (three solid tumor, nine myelodysplasia/acute leukemia, 26.1% of all deaths), and other toxicities (21.7% of all deaths). Complete remission was documented in 98 (73.1%) patients and associated with overall survival, with 13-year estimates of 77.0% and 36.8% for complete remission vs. no-complete remission, respectively. Molecular remission was documented in 39 (65%) out of 60 evaluable patients and associated with improved survival. In multivariate analysis, complete remission achievement had the strongest effect on survival (p<0.001), along with younger age (p=0.002) and female sex (p=0.013). Overall, 50 patients (37.3%) survived with no disease recurrence (18 CHOP-R, 32 R-HDS). This follow-up is the longest reported on follicular lymphoma treated upfront with rituximab-chemotherapy and demonstrates an unprecedented improvement in survival compared to the pre-rituximab era, regardless of the use of intensified or conventional treatment. Complete remission was the most important factor for prolonged survival and a high proportion of patients had prolonged survival in their first remission, raising the issue of curability in follicular lymphoma.

18 June 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
CTCorrado Tarella
Corrado Tarella
SSSimona Sammassimo
Simona Sammassimo
SFSamuele Frassoni
Samuele Frassoni
ADAlida Dominietto
Alida Dominietto
RCRaffaella Cerretti
Raffaella Cerretti
ABAndrea Bacigalupo
Andrea Bacigalupo
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) use in refractory/relapsed B-cell non-Hodgkin lymphoma (R/R B-NHL) has been reduced due to the efficacy of CAR-T-cell therapy as salvage treatment. However, there remains a need for data regarding the long-term outcomes following allo-HSCT, to fully characterize this procedure as benchmark to design further studies on the role of allogeneic stem cell transplantation OBJECTIVE: To assess long-term outcomes of R/R B-NHL patients after allo-HSCT, in a multicenter study among six Italian hematology centers STUDY DESIGN: Data were collected from 285 allo-HSCT procedures performed among 281 R/R B-NHL patients, in 2000-2020. All patients signed informed consent for sharing data with the GITMO/EBMT Registry, the study was approved by the Institutional Review Board of the coordinating center. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), cumulative incidence function (CIF) of disease-related death and non-relapse mortality (NRM). The median age at transplant was 50 years (19-70), with 94 (33%) female patients. Histological subsets included indolent lymphoma (123 patients; 43.3%), aggressive lymphoma (124; 43.7%), and mantle-cell lymphoma (MCL; 37; 13%). At allo-HSCT, 135 patients (47.7%) exhibited complete remission (CR), 63 (22.3%) partial response, 30 (10.6%) stable disease, and 55 (19.4%) progressing disease. Myeloablative regimens were employed in 86 procedures (30.2%). The median follow-up for surviving patients was 8.7 years (0.3-22). Three-year PFS was 43.7% (95% CI 37.9-49.4), 9-year PFS 39.3% (33.4- 45.1), 3-year OS 50.4% (44.5-56.1), and 9-year OS 46.6% (40.5-52.5). Positive predictors of 3-year PFS included indolent lymphoma (55.3%) vs. aggressive (37.9 %) and MCL (27.0%); and CR at allo-HSCT (51.9%) vs non-CR (30.9-38.9%). Similar associations were observed for OS. Among patients in CR, outcomes did not significantly differ among histological subtypes. Among patients not in CR, outcomes were significantly better for indolent lymphoma (3-year PFS: 56.6%), compared to aggressive (26.4%), and MCL (0%). Regarding transplant-procedures, the subgroup receiving post-transplant cyclophosphamide-based program for GVHD prophylaxis had a significantly improved outcome. Overall, 56 patients (19.6%) died from lymphoma progression, with 1-year and 3-year CIF of disease-related death of 15.9% (95% CI 11.9-20.5) and 18.5 (14.2-23.2), respectively. The latest disease recurrence occurred at 5.4 years post-allo-HSCT. Early NRM occurred in 75 patients (12-month CIF 26.1%), and late NRM in 25 patients (5-year CIF 31.2%; 25.9-36.7). At present, 95 patients (33.3%) are long survivors in continuous CR at 5-22 years since transplant. Despite pronounced toxicity, allo-HSCT is effective in high-risk, R/R B-NHL, with 5-year PFS expectancy of ∼40%, and approximately one-third of long survivors in CR. Patients undergoing allo-HSCT in CR exhibited the best results. Among patients not in CR, the greatest benefits were obtained in indolent lymphoma. Allo-HSCT remains a potentially curative option for R/R B-NHL patients and further investigations are warranted to define its possible use in patients unable to undergo or failing CAR-T-cell therapy and/or bispecific monoclonal antibodies.

22 January 2013
Verified
Journal Article
Closed access
AGAngela Gueli
Angela Gueli
DGDaniela Gottardi
Daniela Gottardi
HHHuijing Hu
Huijing Hu
IRIrene Ricca
Irene Ricca
ACAlberto De Crescenzo
Alberto De Crescenzo
CTCorrado Tarella
Corrado Tarella

3 April 2022 in Expert Review of Hematology
Verified
Journal Article
Closed access
SRSafaa Ramadan
Safaa Ramadan
TRTommaso Radice
Tommaso Radice
AIAhmed Ismail
Ahmed Ismail
SFStefano Fiori
Stefano Fiori
CTCorrado Tarella
Corrado Tarella
Primary CNS lymphoma (PCNSL) has traditionally been treated with induction HD-MTX-based chemotherapy, followed by consolidation whole-brain radiotherapy. However, this approach is associated with s...